Dr. Michael Hurwitz, MD, MPH, MsC
Claim this profileYale New Haven Hospital
Studies Non-Small Cell Lung Cancer
Studies Cancer
9 reported clinical trials
19 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
KRAS positive
2Cancer
Stage IV
Stage III
HLA-A positive
Affiliated Hospitals
Clinical Trials Michael Hurwitz, MD, MPH, MsC is currently running
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
Adoptive Cell Therapy
for Cancer
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Recruiting1 award Phase 1
More about Michael Hurwitz, MD, MPH, MsC
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Hurwitz, MD, MPH, MsC has experience with
- LYL797
- ATL001
- Pembrolizumab
- Tumor Infiltrating Lymphocytes (TIL) LN-145
- TSC-204-A0201
- TSC-200-A0201
Breakdown of trials Michael Hurwitz, MD, MPH, MsC has run
Non-Small Cell Lung Cancer
Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Hurwitz, MD, MPH, MsC specialize in?
Michael Hurwitz, MD, MPH, MsC focuses on Non-Small Cell Lung Cancer and Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael Hurwitz, MD, MPH, MsC currently recruiting for clinical trials?
Yes, Michael Hurwitz, MD, MPH, MsC is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Michael Hurwitz, MD, MPH, MsC has studied deeply?
Yes, Michael Hurwitz, MD, MPH, MsC has studied treatments such as LYL797, ATL001, Pembrolizumab.
What is the best way to schedule an appointment with Michael Hurwitz, MD, MPH, MsC?
Apply for one of the trials that Michael Hurwitz, MD, MPH, MsC is conducting.
What is the office address of Michael Hurwitz, MD, MPH, MsC?
The office of Michael Hurwitz, MD, MPH, MsC is located at: Yale New Haven Hospital, New Haven, Connecticut 06510 United States. This is the address for their practice at the Yale New Haven Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.